Share Email Print

Proceedings Paper

Synergism between photochemical and ionizing radiation effects in MCF-7 cells in vitro
Author(s): Gulshan Ara; Terence S. Herman; Archana Varshney; Timothy Korbut; Beverly A. Teicher
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Both PtCl4 (Rh-123)2 and PtCl4 (Nile Blue)2 interact positively in trimodality therapy including each drug, x-ray, and light (400 - 800 nm) in killing human mammary carcinoma cells (MCF-7) in vitro. The combination treatment results in more than additive killing as assessed by product of the surviving fractions and a significant reduction of the shoulder of the x-ray survival curve. Both of the drugs participate in photodynamic therapy (PDT) in drug and light dose dependent manner. The primary subcellular targets for the neutral platinum complexes were indicated to be the nuclear DNA as opposed to the mitochondria for Rh-123 or the lysosomes for Nile Blue. Because the nuclear DNA is also the primary target for ionizing radiation, drug plus light plus x-ray might cause supraadditive killing. Both PtCl4 (Rh-123)2 and PtCl4 (Nile Blue)2 have been reported to be relatively non-toxic in vivo compared to the anionic or cationic compounds currently being used in photodynamic therapy. Based on these results PtCl4 (Rh-123)2 and PtCl4 (Nile Blue)2 have the potential for use in photodynamic therapy and in trimodality therapy.

Paper Details

Date Published: 7 August 1992
PDF: 12 pages
Proc. SPIE 1646, Laser-Tissue Interaction III, (7 August 1992); doi: 10.1117/12.137459
Show Author Affiliations
Gulshan Ara, Dana Farber Cancer Institute (United States)
Terence S. Herman, Dana Farber Cancer Institute (United States)
Archana Varshney, Dana Farber Cancer Institute (United States)
Timothy Korbut, Dana Farber Cancer Institute (United States)
Beverly A. Teicher, Dana Farber Cancer Institute (United States)

Published in SPIE Proceedings Vol. 1646:
Laser-Tissue Interaction III
Steven L. Jacques, Editor(s)

© SPIE. Terms of Use
Back to Top